Associations - ERBB3 expression

ERBB3 expression ERBB3 expression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ERBB3 expression ERBB3 expression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials	ado-trastuzumab emtansine Sensitive: B - Late Trials
ERBB3 expression ERBB3 expression	Colorectal Cancer CRC	ERBB3 expression ERBB3 expression	Colorectal Cancer CRC	U3-1402 Sensitive: C2 – Inclusion Criteria	U3-1402 Sensitive: C2 – Inclusion Criteria
ERBB3 expression ERBB3 expression	Breast Cancer Breast Cancer	ERBB3 expression ERBB3 expression	Breast Cancer Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria	U3-1402 Sensitive: C2 – Inclusion Criteria
ERBB3 expression ERBB3 expression	Colorectal Cancer CRC	ERBB3 expression ERBB3 expression	Colorectal Cancer CRC	cetuximab Sensitive: C3 – Early Trials	cetuximab Sensitive: C3 – Early Trials
ERBB3 expression ERBB3 expression	Endometrial Cancer Endometrial Cancer	ERBB3 expression ERBB3 expression	Endometrial Cancer Endometrial Cancer	lapatinib Resistant: D – Preclinical	lapatinib Resistant: D – Preclinical
ERBB3 expression ERBB3 expression	Bladder Cancer Bladder Cancer	ERBB3 expression ERBB3 expression	Bladder Cancer Bladder Cancer	lapatinib Resistant: D – Preclinical	lapatinib Resistant: D – Preclinical
ERBB3 expression ERBB3 expression	Melanoma Melanoma	ERBB3 expression ERBB3 expression	Melanoma Melanoma	U3-1402 Sensitive: D – Preclinical	U3-1402 Sensitive: D – Preclinical
ERBB3 expression ERBB3 expression	Pancreatic Cancer Pancreatic Cancer	ERBB3 expression ERBB3 expression	Pancreatic Cancer Pancreatic Cancer	afatinib Sensitive: D – Preclinical	afatinib Sensitive: D – Preclinical
ERBB3 expression ERBB3 expression	Pancreatic Cancer Pancreatic Cancer	ERBB3 expression ERBB3 expression	Pancreatic Cancer Pancreatic Cancer	pertuzumab Sensitive: D – Preclinical	pertuzumab Sensitive: D – Preclinical